ClinicalTrialsFinder

National Cancer Institute ( Site 1577)

Vilnius, Vilniaus Miestas, Lithuania

1 recruiting

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC)Prostatic Neoplasms
Merck Sharp & Dohme LLC1,314 enrolled320 locationsNCT06136650